Please try another search
Globalized asset allocation and portfolio management,to achieve the Diversification of Portfolio and the greatest value of fund assets while reducing volatility of the portfolio.
Name | Title | Since | Until |
---|---|---|---|
Shicong Wang | - | 2024 | Now |
Liang Huang | - | 2009 | Now |
Biography | n.a | ||
guofeng ye | - | 2017 | 2018 |
Qing Cai | - | 2015 | 2017 |
Fu Lin Zhu | - | 2014 | 2014 |
Biography | N/A | ||
Yang Qu | - | 2013 | 2014 |
Biography | N.A | ||
Ming Yu Xu | - | 2010 | 2012 |
Biography | N/A | ||
Hao Dong Li | co-Founder | 2008 | 2010 |
Biography | Li joined FBRIM in 2002. Prior to that he was a scientist on the founding team at Human Genome Sciences (“HGSI”). After leaving HGSI in 1996, he co-founded Shenyang Sunshine Pharmaceuticals, the largest biotechnology company in China with $30M in sales. He received 18 biotechnology U.S. patents. Li performed his post-doctoral fellowship at Harvard Medical School under Dr. Bill Haseltine in the area of virology and infectious diseases. | ||
Wei Hong Xie | - | 2007 | 2010 |
Liang Wen | - | 2008 | 2009 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review